Stockysis — AI-Powered Stock News & Sentiment Analysis

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 66.2%

Neg 66.2% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $12 to $7.

Comments

No comments yet. Be the first!